Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.23
ARDM's Cash to Debt is ranked higher than
53% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ARDM: 2.23 )
Ranked among companies with meaningful Cash to Debt only.
ARDM' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 5.24 Max: No Debt
Current: 2.23
Equity to Asset 0.26
ARDM's Equity to Asset is ranked lower than
91% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ARDM: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
ARDM' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.52 Max: 0.92
Current: 0.26
-1.83
0.92
F-Score: 1
Z-Score: -20.26
M-Score: -1.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -30746.67
ARDM's Operating margin (%) is ranked lower than
99% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. ARDM: -30746.67 )
Ranked among companies with meaningful Operating margin (%) only.
ARDM' s Operating margin (%) Range Over the Past 10 Years
Min: -30746.67  Med: -470.36 Max: -11.49
Current: -30746.67
-30746.67
-11.49
Net-margin (%) -32717.14
ARDM's Net-margin (%) is ranked lower than
99% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ARDM: -32717.14 )
Ranked among companies with meaningful Net-margin (%) only.
ARDM' s Net-margin (%) Range Over the Past 10 Years
Min: -32717.14  Med: -276.33 Max: 13.86
Current: -32717.14
-32717.14
13.86
ROE (%) -181.96
ARDM's ROE (%) is ranked lower than
96% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. ARDM: -181.96 )
Ranked among companies with meaningful ROE (%) only.
ARDM' s ROE (%) Range Over the Past 10 Years
Min: -808.13  Med: -183.67 Max: 12.78
Current: -181.96
-808.13
12.78
ROA (%) -97.80
ARDM's ROA (%) is ranked lower than
96% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ARDM: -97.80 )
Ranked among companies with meaningful ROA (%) only.
ARDM' s ROA (%) Range Over the Past 10 Years
Min: -102.39  Med: -62.71 Max: 8.91
Current: -97.8
-102.39
8.91
ROC (Joel Greenblatt) (%) -10985.61
ARDM's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. ARDM: -10985.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARDM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10985.61  Med: -597.81 Max: 1095.34
Current: -10985.61
-10985.61
1095.34
Revenue Growth (3Y)(%) 99.50
ARDM's Revenue Growth (3Y)(%) is ranked higher than
97% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. ARDM: 99.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARDM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.4  Med: -8 Max: 136.2
Current: 99.5
-81.4
136.2
EBITDA Growth (3Y)(%) -2.80
ARDM's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. ARDM: -2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARDM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.1  Med: -31.25 Max: 10.6
Current: -2.8
-61.1
10.6
EPS Growth (3Y)(%) -9.90
ARDM's EPS Growth (3Y)(%) is ranked lower than
71% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. ARDM: -9.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARDM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.3  Med: -32.95 Max: 13.8
Current: -9.9
-56.3
13.8
» ARDM's 10-Y Financials

Financials (Next Earnings Date: 2017-03-15)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ARDM Guru Trades in Q4 2015

Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q1 2016

ARDM Guru Trades in Q1 2016

John Paulson 19,662 sh (New)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q2 2016

ARDM Guru Trades in Q2 2016

John Paulson 65,903 sh (+235.18%)
First Eagle Investment 3,854,730 sh (unchged)
Steven Cohen 320,585 sh (unchged)
» More
Q3 2016

ARDM Guru Trades in Q3 2016

John Paulson 146,918 sh (+122.93%)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 334510    SIC: 3845
Compare:NAS:SPHS, NAS:CPHR, NAS:SCYX, NAS:STDY, NAS:CPIX, NAS:MSLI, NAS:LPCN, NAS:ADMP, NAS:CPRX, NAS:PSDV, NAS:JNP, NAS:MEIP, NAS:EPIX, OTCPK:NRIFF, OTCPK:MRPHF, NAS:FCSC, NAS:NEOS, NAS:IMMY, OTCPK:BKIT, NAS:BPTH » details
Aradigm Corp is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases.

Aradigm Corp, a California corporation was incorporated on January 30, 1991 . It is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin or Pulmaquin ARD-3150 and Lipoquin ARD-3100 that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. It competes with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.

Top Ranked Articles about Aradigm Corp

First Eagle Adds to Stake in Aradigm Guru buys more than half a million shares in pharmaceutical company
First Eagle Investment (Trades, Portfolio) raised its stake in Aradigm Corp. (NASDAQ:ARDM), a Hayward, California-based pharmaceutical company, by nearly 15% with the purchase of 575,815 shares on April 25. Read more...

Ratios

vs
industry
vs
history
P/B 3.55
ARDM's P/B is ranked lower than
65% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ARDM: 3.55 )
Ranked among companies with meaningful P/B only.
ARDM' s P/B Range Over the Past 10 Years
Min: 0.76  Med: 3.16 Max: 232.43
Current: 3.55
0.76
232.43
P/S 331.67
ARDM's P/S is ranked lower than
98% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. ARDM: 331.67 )
Ranked among companies with meaningful P/S only.
ARDM' s P/S Range Over the Past 10 Years
Min: 1.21  Med: 9.84 Max: 1146.67
Current: 331.67
1.21
1146.67
Current Ratio 5.27
ARDM's Current Ratio is ranked higher than
80% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ARDM: 5.27 )
Ranked among companies with meaningful Current Ratio only.
ARDM' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.1 Max: 21.99
Current: 5.27
0.94
21.99
Quick Ratio 5.27
ARDM's Quick Ratio is ranked higher than
82% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. ARDM: 5.27 )
Ranked among companies with meaningful Quick Ratio only.
ARDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.07 Max: 21.99
Current: 5.27
0.94
21.99
Days Sales Outstanding 139.05
ARDM's Days Sales Outstanding is ranked lower than
83% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. ARDM: 139.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.34  Med: 14.93 Max: 571.49
Current: 139.05
2.34
571.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.00
ARDM's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. ARDM: -33.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.3  Med: -35.7 Max: -11.9
Current: -33
-63.3
-11.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.77
ARDM's Price/Net Cash is ranked higher than
64% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. ARDM: 6.77 )
Ranked among companies with meaningful Price/Net Cash only.
ARDM' s Price/Net Cash Range Over the Past 10 Years
Min: 1.47  Med: 6.15 Max: 362.93
Current: 6.77
1.47
362.93
Price/Net Current Asset Value 3.89
ARDM's Price/Net Current Asset Value is ranked higher than
74% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.66 vs. ARDM: 3.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARDM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.44  Med: 4.5 Max: 88.72
Current: 3.89
1.44
88.72
Price/Tangible Book 3.75
ARDM's Price/Tangible Book is ranked lower than
54% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ARDM: 3.75 )
Ranked among companies with meaningful Price/Tangible Book only.
ARDM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.25  Med: 3.32 Max: 205.41
Current: 3.75
1.25
205.41
Price/Median PS Value 35.00
ARDM's Price/Median PS Value is ranked lower than
100% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. ARDM: 35.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ARDM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.65 Max: 114.67
Current: 35
0.13
114.67
Earnings Yield (Greenblatt) (%) -236.30
ARDM's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ARDM: -236.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARDM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -264.82  Med: 437.2 Max: 73513.7
Current: -236.3
-264.82
73513.7

More Statistics

Revenue (TTM) (Mil) $0.11
EPS (TTM) $ -2.33
Beta1.36
Short Percentage of Float0.77%
52-Week Range $2.00 - 7.19
Shares Outstanding (Mil)14.95
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
First Eagle Adds to Stake in Aradigm Apr 28 2016 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 02 2016
Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Dec 02 2016
Don’t Write Off Aradigm Corporation (ARDM) Just Yet Dec 02 2016
Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials Dec 01 2016
Aradigm posts mixed late-stage data on inhaled antibiotic Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
ARADIGM CORP Financials Nov 18 2016
ARADIGM CORP Files SEC form 10-Q, Quarterly Report Nov 10 2016
Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Nov 10 2016
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Aradigm reports 3Q loss Nov 09 2016
Aradigm reports 3Q loss Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin Oct 18 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin Oct 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)